Riociguat for Patients With Pulmonary Hypertension Caused by Systolic Left Ventricular Dysfunction | Zendy

Diana Bonderman | Zendy; Stefano Ghio | Zendy; Stephan B. Felix | Zendy; Hossein A. Ghofrani | Zendy; Evangelos D. Michelakis | Zendy; Veselin Mitrović | Zendy; Ronald J. Oudiz | Zendy; Francis Boateng | Zendy; AndreaViviana Scalise | Zendy; Lothar Roessig | Zendy; Marc J. Semigran | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Riociguat for Patients With Pulmonary Hypertension Caused by Systolic Left Ventricular Dysfunction

Author(s) -

Diana Bonderman,

Stefano Ghio,

Stephan B. Felix,

Hossein A. Ghofrani,

Evangelos D. Michelakis,

Veselin Mitrović,

Ronald J. Oudiz,

Francis Boateng,

AndreaViviana Scalise,

Lothar Roessig,

Marc J. Semigran

Publication year - 2013

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.113.001458

Subject(s) - medicine , riociguat , pulmonary hypertension , cardiology , chronic thromboembolic pulmonary hypertension

Pulmonary hypertension caused by systolic left ventricular dysfunction is associated with significant morbidity and mortality; however, no treatment is approved for this indication. We hypothesized that riociguat, a novel soluble guanylate cyclase stimulator, would have beneficial hemodynamic effects in patients with pulmonary hypertension caused by systolic left ventricular dysfunction.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research